查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1654201

藥物研發外包市場規模、佔有率、趨勢分析報告：按藥物類型、工作流程、治療領域、服務類型、最終用途、地區、細分預測，2025-2030 年

Drug Discovery Outsourcing Market Size, Share & Trends Analysis Report By Drug Type (Small, Large Molecules), By Workflow, By Therapeutics Area, By Service Type, By End Use, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

藥物研發外包市場的成長與趨勢

根據Grand View Research, Inc.的最新報告，全球藥物研發外包市場規模預計到2030年將達到102.3億美元，2025年至2030年期間的複合年成長率為7.58%。

藥物研發是一個昂貴且耗時的過程。因此，製藥和生物技術公司選擇將其研究活動外包給學術機構和私人公司（CRO）。公共和私營部門組織之間日益增多的合作正在加速藥物研發進程，從而導致全球對藥物研發外包服務的需求增加。

預計這種情況將在疫情過後持續下去。慢性疾病患者的增加給企業帶來了開發延長壽命藥物的壓力。根據聯合國估計，2015年至2020年期間年滿65歲的人預期壽命將延長17年。公司積極尋求外包的主要治療領域包括腫瘤學、循環系統和抗感染疾病。 2020 年 11 月，阿斯特捷利康與九家領先的癌症治療中心合作，加速對一些最難治療的癌症的研究。該公司計劃為網路成員的臨床和臨床前研究提案提供資金。

COVID-19 疫情證明了藥物研發的價值。就在世界各地人們熱切等待疫苗的同時，多家公司正積極致力於研發有效的新冠肺炎疫苗。輝瑞和 BioNTech SE 聯合研發的疫苗在對具有對抗病毒潛力的病毒株進行第三階段臨床試驗後，成為全球首個獲得核准。至於臨床測試，許多已經停止，但有些透過採用遠端監控技術仍在繼續運作。因此，這場疫情讓製藥業成為了焦點，藥物研發外包成為開發有效治療方法病毒方法的關鍵方面。預計這將在未來兩年內推動市場收益上升，形成短期繁榮，此後市場預計將恢復正常成長軌跡。

藥物研發外包市場報告重點

  • 根據工作流程細分，市場分為目標識別和篩檢、目標檢驗和功能資訊學、先導化合物識別和候選藥物最佳化、臨床前開發和其他相關工作流程。
  • 依治療領域分為呼吸系統、疼痛和麻醉、腫瘤科、眼科、血液科、循環系統、內分泌科、胃腸系統、免疫調節、抗感染、中樞神經系統、皮膚科、泌尿生殖系統。
  • 根據藥物類型，市場分為小分子和大分子（生物製藥）。
  • 根據服務類型，市場分為化學服務和生物服務。由於各行業小分子外包計劃的增加，化學品行業在 2024 年佔據了最大的收入佔有率。
  • 根據最終用途，市場分為製藥和生物技術公司、學術機構和其他。 2024年，製藥和生技公司將佔據市場主導地位，佔據最大的收益佔有率。
  • 2024 年，亞太市場佔有最大的市場佔有率，為 45.99%。這種成長可歸因於多種因素，包括醫療支出的增加和藥物需求的增加。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第 3 章藥物研發外包市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/支持市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 藥物研發外包市場分析工具
    • 產業分析 – 波特五大分析
    • PESTEL 分析
    • COVID-19影響分析

第 4 章 藥物研發外包市場：工作流程的估計與趨勢分析

  • 藥物研發外包市場，依工作流程：細分儀表板
  • 藥物研發外包市場，依工作流程：變異分析
  • 按工作流程，2018-2030 年
  • 受試者辨識與篩檢
  • 目標檢驗和功能資訊學
  • 潛在客戶識別和候選人最佳化
  • 臨床前開發
  • 其他

第5章 藥物研發外包市場：依治療領域的估計與趨勢分析

  • 藥物研發外包市場（依治療領域）：細分儀表板
  • 藥物研發外包市場（依治療領域）波動分析
  • 依治療領域，2018-2030 年
  • 呼吸系統
  • 疼痛和麻醉
  • 瘤
  • 眼科
  • 血
  • 循環系統
  • 內分泌
  • 消化道
  • 免疫調節
  • 抗感染
  • 中樞神經系統
  • 皮膚科
  • 泌尿生殖系統

第6章 藥物研發外包市場：按藥物類型進行的估計和趨勢分析

  • 藥物研發外包市場（依藥物類型）：細分儀表板
  • 藥物研發外包市場（依藥物類型）：波動分析
  • 藥物類型，2018-2030
  • 小分子
    • 小分子量市場，2018-2030
  • 聚合物（生物製藥）
    • 聚合物（生物製藥）市場，2018-2030

第7章 藥物研發外包市場：按服務類型分類的估計和趨勢分析

  • 藥物研發外包市場，依服務類型：細分儀表板
  • 藥物研發外包市場，依服務類型：波動分析
  • 依服務類型，2018-2030 年
  • 化學服務
    • 化學服務市場，2018 - 2030 年
  • 生物服務
    • 生物服務市場，2018 - 2030 年

第 8 章：藥物研發外包市場：依最終用途的估計與趨勢分析

  • 藥物研發外包市場，依最終用途：細分儀表板
  • 藥物研發外包市場（依最終用途分類）：差異分析
  • 按最終用途分類，2018-2030 年
  • 製藥和生物技術公司
    • 製藥和生物技術公司市場，2018-2030 年
  • 學術機構
    • 學術機構市場，2018-2030 年

第9章 藥物研發外包市場：按地區估計和趨勢分析

  • 2024 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 全球區域市場概況
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 義大利
    • 法國
    • 西班牙
    • 荷蘭
    • 比利時
    • 瑞士
    • 俄羅斯
    • 瑞典
  • 亞太地區
    • 中國
    • 日本
    • 澳洲
    • 韓國
    • 印度
    • 泰國
    • 馬來西亞
    • 印尼
    • 新加坡
    • 菲律賓
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
    • 智利
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特
    • 以色列
    • 埃及

第10章 競爭格局

  • 市場參與企業分類
  • 2024 年公司市場佔有率分析
  • 公司簡介
    • Albany Molecular Research Inc.
    • EVOTEC
    • Laboratory Corporation of America Holdings
    • GenScript
    • Pharmaceutical Product Development, LLC
    • Charles River Laboratories
    • WuXi AppTec
    • Merck &Co., Inc.
    • Thermo Fisher Scientific Inc
    • Dalton Pharma Services
    • Oncodesign
    • Jubilant Biosys
    • DiscoverX Corp.
    • QIAGEN
    • Eurofins SE
    • Syngene International Limited
    • Dr. Reddy Laboratories Ltd.
    • Pharmaron Beijing Co., Ltd.
    • TCG Lifesciences Pvt Ltd.
    • Domainex Ltd.
Product Code: GVR-2-68038-392-8

Drug Discovery Outsourcing Market Growth & Trends:

The global drug discovery outsourcing market size is expected to reach USD 10.23 billion by 2030 and is expected to expand at a CAGR of 7.58% from 2025 to 2030, according to a new report by Grand View Research, Inc., The COVID-19 pandemic has brought pharmaceutical companies in limelight. Drug discovery is a costly and lengthy process. This has urged pharmaceutical and biotech companies to opt for outsourcing their research activities to academic and private Contract Research Organizations (CROs). Rising partnerships between public or private entities accelerate drug discovery processes, which, in turn, increase the global demand for outsourcing services for drug discovery.

This scenario is expected to sustain post-Covid implications as well. A rise in cases of chronic diseases has urged companies to develop medicines that extend life expectancy. According to the United Nations, people aged 65 years between 2015 and 2020 are expected to live an additional 17 years. Some of the key therapeutic areas where companies are actively involved in outsourcing include oncology, cardiovascular, and anti-infectives. In November 2020, AstraZeneca collaborated with 9 of the foremost oncology medical centers to expedite research in some of the hardest-to-treat cancers. The company will be funding clinical and non-clinical research proposals from members of this network.

The COVID-19 pandemic has demonstrated the value of drug discovery and development. People across the world are waiting for a vaccine while several companies are proactively involved in developing an effective vaccine to combat COVID-19. Pfizer Inc. and BioNTech SE received first approval for the vaccine following a worldwide Phase 3 trial of a potential strain to combat the virus. As for clinical trials, many of them are halted, while some are functional by adopting remote monitoring technologies. Thus, the pandemic has brought the pharmaceutical industry to center stage with drug discovery outsourcing becoming a key aspect to develop effective treatments against the virus. This is expected to boost the market revenue for the next 2 years i.e. a short-term boom, after which it shall regain its original growth curve.

Drug Discovery Outsourcing Market Report Highlights:

  • On the basis of workflow segment, the market is segmented into target identification & screening, target validation & functional informatics, lead identification & candidate optimization, preclinical development, and other associated workflow.
  • On the basis of therapeutics area segment, the market is segmented into Respiratory System, Pain and Anesthesia, Oncology, Ophthalmology, Hematology, Cardiovascular, Endocrine, Gastrointestinal, Immunomodulation, Anti-Infective, Central Nervous System, Dermatology, and Genitourinary System.
  • On the basis of drug type segment, the market is segmented into Small Molecules, and Large Molecules (Biopharmaceuticals).
  • On the basis of service type segment, the market is segmented into Chemistry Services, and Biology Services. The chemistry segment dominated the market with the largest revenue share in 2024, owing to increasing number of outsourcing projects for small molecules across the industry.
  • On the basis of end use segment, the market is segmented into Pharmaceutical & Biotechnology companies, Academic Institutes, and Others. The pharmaceutical & biotechnology companies segment dominated the market with the largest revenue share in 2024.
  • Asia Pacific market held the largest market share of 45.99% in 2024. This growth can be attributed to various factors, such as rising healthcare expenditure and growing demand for pharmaceutical products.

Table of Contents

Chapter 1. Research Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Workflow
    • 1.2.2. Therapeutics Area
    • 1.2.3. Drug type
    • 1.2.4. Service Type
    • 1.2.5. End Use
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Information Or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity Flow Analysis
    • 1.7.2. Parent Market Analysis
  • 1.8. List Of Secondary Sources
  • 1.9. List Of Abbreviations
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Drug Discovery Outsourcing Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing R&D In Biopharmaceutical Industry
      • 3.2.1.2. Increasing demand for outsourcing Services in Drug Development
      • 3.2.1.3. Increasing number of partnerships in drug discovery research
      • 3.2.1.4. Technological advancements in drug discovery
      • 3.2.1.5. Rising incidence rate of metabolic, genetic, and other chronic diseases
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Presence of open-source software packages for drug discovery
      • 3.2.2.2. High manufacturing costs coupled with high risk of drug failure
  • 3.3. Drug Discovery Outsourcing Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's Five Analysis
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Drug Discovery Outsourcing Market: Workflow Estimates & Trend Analysis

  • 4.1. Drug Discovery Outsourcing Market, By Workflow: Segment Dashboard
  • 4.2. Drug Discovery Outsourcing Market, By Workflow: Movement Analysis
  • 4.3. Drug Discovery Outsourcing Market Estimates & Forecasts, By Workflow, 2018 - 2030
  • 4.4. Target Identification & Screening
    • 4.4.1. Target Identification & Screening Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Target Validation & Functional Informatics
    • 4.5.1. Target Validation & Functional Informatics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Lead Identification & Candidate Optimization
    • 4.6.1. Lead Identification & Candidate Optimization Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. Preclinical Development
    • 4.7.1. Preclinical Development Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.8. Other Associate Workflow
    • 4.8.1. Other Associate Workflow Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Drug Discovery Outsourcing Market: Therapeutics Area Estimates & Trend Analysis

  • 5.1. Drug Discovery Outsourcing Market, By Therapeutics Area: Segment Dashboard
  • 5.2. Drug Discovery Outsourcing Market, By Therapeutics Area: Movement Analysis
  • 5.3. Drug Discovery Outsourcing Market Estimates & Forecasts, By Therapeutics, 2018 - 2030
  • 5.4. Respiratory System
    • 5.4.1. Respiratory System Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Pain and Anesthesia
    • 5.5.1. Pain and Anesthesia Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Oncology
    • 5.6.1. Oncology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7. Ophthalmology
    • 5.7.1. Ophthalmology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.8. Hematology
    • 5.8.1. Hematology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.9. Cardiovascular
    • 5.9.1. Cardiovascular Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.10. Endocrine
    • 5.10.1. Endocrine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.11. Gastrointestinal
    • 5.11.1. Gastrointestinal Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.12. Immunomodulation
    • 5.12.1. Immunomodulation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.13. Anti-Infective
    • 5.13.1. Anti-Infective Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.14. Central Nervous System
    • 5.14.1. Central Nervous System Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.15. Dermatology
    • 5.15.1. Dermatology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.16. Genitourinary System
    • 5.16.1. Genitourinary System Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Drug Discovery Outsourcing Market: Drug Type Estimates & Trend Analysis

  • 6.1. Drug Discovery Outsourcing Market, By Drug Type: Segment Dashboard
  • 6.2. Drug Discovery Outsourcing Market, By Drug Type: Movement Analysis
  • 6.3. Drug Discovery Outsourcing Market Estimates & Forecasts, By Drug Type, 2018 - 2030
  • 6.4. Small Molecules
    • 6.4.1. Small Molecules Market, 2018 to 2030, (USD Million)
  • 6.5. Large Molecules (Biopharmaceuticals)
    • 6.5.1. Large Molecules (Biopharmaceuticals) Market, 2018 to 2030, (USD Million)

Chapter 7. Drug Discovery Outsourcing Market: Service Type Estimates & Trend Analysis

  • 7.1. Drug Discovery Outsourcing Market, By Service Type: Segment Dashboard
  • 7.2. Drug Discovery Outsourcing Market, By Service Type: Movement Analysis
  • 7.3. Drug Discovery Outsourcing Market Estimates & Forecasts, By Service Type, 2018 - 2030
  • 7.4. Chemistry Services
    • 7.4.1. Chemistry Services Market, 2018 to 2030, (USD Million)
  • 7.5. Biology Services
    • 7.5.1. Biology Services Market, 2018 to 2030, (USD Million)

Chapter 8. Drug Discovery Outsourcing Market: End Use Estimates & Trend Analysis

  • 8.1. Drug Discovery Outsourcing Market, By End Use: Segment Dashboard
  • 8.2. Drug Discovery Outsourcing Market, By End Use: Movement Analysis
  • 8.3. Drug Discovery Outsourcing Market Estimates & Forecasts, By End Use, 2018 - 2030
  • 8.4. Pharmaceutical & Biotechnology companies
    • 8.4.1. Pharmaceutical & Biotechnology Companies Market, 2018 to 2030, (USD Million)
  • 8.5. Academic Institutes
    • 8.5.1. Academic Institutes Market, 2018 to 2030, (USD Million)

Chapter 9. Drug Discovery Outsourcing Market: Regional Estimates & Trend Analysis

  • 9.1. Regional Market Share Analysis, 2024 & 2030
  • 9.2. Regional Market Dashboard
  • 9.3. Global Regional Market Snapshot
  • 9.4. North America
    • 9.4.1. North America Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.4.2. U.S
      • 9.4.2.1. Key Country Dynamics
      • 9.4.2.2. Competitive Scenario
      • 9.4.2.3. Regulatory Framework
      • 9.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.4.3. Canada
      • 9.4.3.1. Key Country Dynamics
      • 9.4.3.2. Competitive Scenario
      • 9.4.3.3. Regulatory Framework
      • 9.4.3.4. Canada Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.4.4. Mexico
      • 9.4.4.1. Key Country Dynamics
      • 9.4.4.2. Competitive Scenario
      • 9.4.4.3. Regulatory Framework
      • 9.4.4.4. Mexico Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.5. Europe
    • 9.5.1. Europe Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.5.2. UK
      • 9.5.2.1. Key Country Dynamics
      • 9.5.2.2. Competitive Scenario
      • 9.5.2.3. Regulatory Framework
      • 9.5.2.4. UK Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.5.3. Germany
      • 9.5.3.1. Key Country Dynamics
      • 9.5.3.2. Competitive Scenario
      • 9.5.3.3. Regulatory Framework
      • 9.5.3.4. Germany Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.5.4. Italy
      • 9.5.4.1. Key Country Dynamics
      • 9.5.4.2. Competitive Scenario
      • 9.5.4.3. Regulatory Framework
      • 9.5.4.4. Italy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.5.5. France
      • 9.5.5.1. Key Country Dynamics
      • 9.5.5.2. Competitive Scenario
      • 9.5.5.3. Regulatory Framework
      • 9.5.5.4. France Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.5.6. Spain
      • 9.5.6.1. Key Country Dynamics
      • 9.5.6.2. Competitive Scenario
      • 9.5.6.3. Regulatory Framework
      • 9.5.6.4. Spain Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.5.7. Netherland
      • 9.5.7.1. Key Country Dynamics
      • 9.5.7.2. Competitive Scenario
      • 9.5.7.3. Regulatory Framework
      • 9.5.7.4. Netherland Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.5.8. Belgium
      • 9.5.8.1. Key Country Dynamics
      • 9.5.8.2. Competitive Scenario
      • 9.5.8.3. Regulatory Framework
      • 9.5.8.4. Belgium Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.5.9. Switzerland
      • 9.5.9.1. Key Country Dynamics
      • 9.5.9.2. Competitive Scenario
      • 9.5.9.3. Regulatory Framework
      • 9.5.9.4. Switzerland Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.5.10. Russia
      • 9.5.10.1. Key Country Dynamics
      • 9.5.10.2. Competitive Scenario
      • 9.5.10.3. Regulatory Framework
      • 9.5.10.4. Russia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.5.11. Sweden
      • 9.5.11.1. Key Country Dynamics
      • 9.5.11.2. Competitive Scenario
      • 9.5.11.3. Regulatory Framework
      • 9.5.11.4. Sweden Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.6. Asia Pacific
    • 9.6.1. Asia Pacific Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.6.2. China
      • 9.6.2.1. Key Country Dynamics
      • 9.6.2.2. Competitive Scenario
      • 9.6.2.3. Regulatory Framework
      • 9.6.2.4. China Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.6.3. Japan
      • 9.6.3.1. Key Country Dynamics
      • 9.6.3.2. Competitive Scenario
      • 9.6.3.3. Regulatory Framework
      • 9.6.3.4. Japan Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.6.4. Australia
      • 9.6.4.1. Key Country Dynamics
      • 9.6.4.2. Competitive Scenario
      • 9.6.4.3. Regulatory Framework
      • 9.6.4.4. Australia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.6.5. South Korea
      • 9.6.5.1. Key Country Dynamics
      • 9.6.5.2. Competitive Scenario
      • 9.6.5.3. Regulatory Framework
      • 9.6.5.4. South Korea Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.6.6. India
      • 9.6.6.1. Key Country Dynamics
      • 9.6.6.2. Competitive Scenario
      • 9.6.6.3. Regulatory Framework
      • 9.6.6.4. India Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.6.7. Thailand
      • 9.6.7.1. Key Country Dynamics
      • 9.6.7.2. Competitive Scenario
      • 9.6.7.3. Regulatory Framework
      • 9.6.7.4. Thailand Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.6.8. Malaysia
      • 9.6.8.1. Key Country Dynamics
      • 9.6.8.2. Competitive Scenario
      • 9.6.8.3. Regulatory Framework
      • 9.6.8.4. Malaysia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.6.9. Indonesia
      • 9.6.9.1. Key Country Dynamics
      • 9.6.9.2. Competitive Scenario
      • 9.6.9.3. Regulatory Framework
      • 9.6.9.4. Indonesia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.6.10. Singapore
      • 9.6.10.1. Key Country Dynamics
      • 9.6.10.2. Competitive Scenario
      • 9.6.10.3. Regulatory Framework
      • 9.6.10.4. Singapore Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.6.11. Philippines
      • 9.6.11.1. Key Country Dynamics
      • 9.6.11.2. Competitive Scenario
      • 9.6.11.3. Regulatory Framework
      • 9.6.11.4. Philippines Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.7. Latin America
    • 9.7.1. Latin America Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.7.2. Brazil
      • 9.7.2.1. Key Country Dynamics
      • 9.7.2.2. Competitive Scenario
      • 9.7.2.3. Regulatory Framework
      • 9.7.2.4. Brazil Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.7.3. Argentina
      • 9.7.3.1. Key Country Dynamics
      • 9.7.3.2. Competitive Scenario
      • 9.7.3.3. Regulatory Framework
      • 9.7.3.4. Argentina Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.7.4. Colombia
      • 9.7.4.1. Key Country Dynamics
      • 9.7.4.2. Competitive Scenario
      • 9.7.4.3. Regulatory Framework
      • 9.7.4.4. Colombia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.7.5. Chile
      • 9.7.5.1. Key Country Dynamics
      • 9.7.5.2. Competitive Scenario
      • 9.7.5.3. Regulatory Framework
      • 9.7.5.4. Chile Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.8. MEA
    • 9.8.1. MEA Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.8.2. South Africa
      • 9.8.2.1. Key Country Dynamics
      • 9.8.2.2. Competitive Scenario
      • 9.8.2.3. Regulatory Framework
      • 9.8.2.4. South Africa Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.8.3. Saudi Arabia
      • 9.8.3.1. Key Country Dynamics
      • 9.8.3.2. Competitive Scenario
      • 9.8.3.3. Regulatory Framework
      • 9.8.3.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.8.4. UAE
      • 9.8.4.1. Key Country Dynamics
      • 9.8.4.2. Competitive Scenario
      • 9.8.4.3. Regulatory Framework
      • 9.8.4.4. UAE Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.8.5. Kuwait
      • 9.8.5.1. Key Country Dynamics
      • 9.8.5.2. Competitive Scenario
      • 9.8.5.3. Regulatory Framework
      • 9.8.5.4. Kuwait Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.8.6. Israel
      • 9.8.6.1. Key Country Dynamics
      • 9.8.6.2. Competitive Scenario
      • 9.8.6.3. Regulatory Framework
      • 9.8.6.4. Israel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 9.8.7. Egypt
      • 9.8.7.1. Key Country Dynamics
      • 9.8.7.2. Competitive Scenario
      • 9.8.7.3. Regulatory Framework
      • 9.8.7.4. Egypt Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 10. Competitive Landscape

  • 10.1. Market Participant Categorization
  • 10.2. Company Market Share Analysis, 2024
  • 10.3. Company Profiles
    • 10.3.1. Albany Molecular Research Inc.
      • 10.3.1.1. Company Overview
      • 10.3.1.2. Financial Performance
      • 10.3.1.3. Service Benchmarking
      • 10.3.1.4. Strategic Initiatives
    • 10.3.2. EVOTEC
      • 10.3.2.1. Company Overview
      • 10.3.2.2. Financial Performance
      • 10.3.2.3. Service Benchmarking
      • 10.3.2.4. Strategic Initiatives
    • 10.3.3. Laboratory Corporation of America Holdings
      • 10.3.3.1. Company Overview
      • 10.3.3.2. Financial Performance
      • 10.3.3.3. Service Benchmarking
      • 10.3.3.4. Strategic Initiatives
    • 10.3.4. GenScript
      • 10.3.4.1. Company Overview
      • 10.3.4.2. Financial Performance
      • 10.3.4.3. Service Benchmarking
      • 10.3.4.4. Strategic Initiatives
    • 10.3.5. Pharmaceutical Product Development, LLC
      • 10.3.5.1. Company Overview
      • 10.3.5.2. Financial Performance
      • 10.3.5.3. Service Benchmarking
      • 10.3.5.4. Strategic Initiatives
    • 10.3.6. Charles River Laboratories
      • 10.3.6.1. Company Overview
      • 10.3.6.2. Financial Performance
      • 10.3.6.3. Service Benchmarking
      • 10.3.6.4. Strategic Initiatives
    • 10.3.7. WuXi AppTec
      • 10.3.7.1. Company Overview
      • 10.3.7.2. Financial Performance
      • 10.3.7.3. Service Benchmarking
      • 10.3.7.4. Strategic Initiatives
    • 10.3.8. Merck & Co., Inc.
      • 10.3.8.1. Company Overview
      • 10.3.8.2. Financial Performance
      • 10.3.8.3. Service Benchmarking
      • 10.3.8.4. Strategic Initiatives
    • 10.3.9. Thermo Fisher Scientific Inc
      • 10.3.9.1. Company Overview
      • 10.3.9.2. Financial Performance
      • 10.3.9.3. Service Benchmarking
      • 10.3.9.4. Strategic Initiatives
    • 10.3.10. Dalton Pharma Services
      • 10.3.10.1. Company Overview
      • 10.3.10.2. Financial Performance
      • 10.3.10.3. Service Benchmarking
      • 10.3.10.4. Strategic Initiatives
    • 10.3.11. Oncodesign
      • 10.3.11.1. Company Overview
      • 10.3.11.2. Financial Performance
      • 10.3.11.3. Service Benchmarking
      • 10.3.11.4. Strategic Initiatives
    • 10.3.12. Jubilant Biosys
      • 10.3.12.1. Company Overview
      • 10.3.12.2. Financial Performance
      • 10.3.12.3. Service Benchmarking
      • 10.3.12.4. Strategic Initiatives
    • 10.3.13. DiscoverX Corp.
      • 10.3.13.1. Company Overview
      • 10.3.13.2. Financial Performance
      • 10.3.13.3. Service Benchmarking
      • 10.3.13.4. Strategic Initiatives
    • 10.3.14. QIAGEN
      • 10.3.14.1. Company Overview
      • 10.3.14.2. Financial Performance
      • 10.3.14.3. Service Benchmarking
      • 10.3.14.4. Strategic Initiatives
    • 10.3.15. Eurofins SE
      • 10.3.15.1. Company Overview
      • 10.3.15.2. Financial Performance
      • 10.3.15.3. Service Benchmarking
      • 10.3.15.4. Strategic Initiatives
    • 10.3.16. Syngene International Limited
      • 10.3.16.1. Company Overview
      • 10.3.16.2. Financial Performance
      • 10.3.16.3. Service Benchmarking
      • 10.3.16.4. Strategic Initiatives
    • 10.3.17. Dr. Reddy Laboratories Ltd.
      • 10.3.17.1. Company Overview
      • 10.3.17.2. Financial Performance
      • 10.3.17.3. Service Benchmarking
      • 10.3.17.4. Strategic Initiatives
    • 10.3.18. Pharmaron Beijing Co., Ltd.
      • 10.3.18.1. Company Overview
      • 10.3.18.2. Financial Performance
      • 10.3.18.3. Service Benchmarking
      • 10.3.18.4. Strategic Initiatives
    • 10.3.19. TCG Lifesciences Pvt Ltd.
      • 10.3.19.1. Company Overview
      • 10.3.19.2. Financial Performance
      • 10.3.19.3. Service Benchmarking
      • 10.3.19.4. Strategic Initiatives
    • 10.3.20. Domainex Ltd.
      • 10.3.20.1. Company Overview
      • 10.3.20.2. Financial Performance
      • 10.3.20.3. Service Benchmarking
      • 10.3.20.4. Strategic Initiatives

List of Tables

  • Table. 1 List of Secondary Sources
  • Table. 2 List of Abbreviations
  • Table. 3 Global Drug Discovery Outsourcing, by Workflow, 2018 - 2030 (USD Million)
  • Table. 4 Global Drug Discovery Outsourcing, by Therapeutics Area, 2018 - 2030 (USD Million)
  • Table. 5 Global Drug Discovery Outsourcing, by Drug Type, 2018 - 2030 (USD Million)
  • Table. 6 Global Drug Discovery Outsourcing, by Service Type, 2018 - 2030 (USD Million)
  • Table. 7 Global Drug Discovery Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table. 8 North America Discovery Outsourcing, by Country, 2018 - 2030 (USD Million)
  • Table. 9 North America Drug Discovery Outsourcing, by Workflow, 2018 - 2030 (USD Million)
  • Table. 10 North America Drug Discovery Outsourcing, by Therapeutics Area, 2018 - 2030 (USD Million)
  • Table. 11 North America Drug Discovery Outsourcing, by Drug Type, 2018 - 2030 (USD Million)
  • Table. 12 North America Drug Discovery Outsourcing, by Service Type, 2018 - 2030 (USD Million)
  • Table. 13 North America Drug Discovery Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table. 14 U.S. Drug Discovery Outsourcing, by Workflow, 2018 - 2030 (USD Million)
  • Table. 15 U.S. Drug Discovery Outsourcing, by Therapeutics Area, 2018 - 2030 (USD Million)
  • Table. 16 U.S. Drug Discovery Outsourcing, by Drug Type, 2018 - 2030 (USD Million)
  • Table. 17 U.S. Drug Discovery Outsourcing, by Service Type, 2018 - 2030 (USD Million)
  • Table. 18 U.S. Drug Discovery Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table. 19 Canada Drug Discovery Outsourcing, by Workflow, 2018 - 2030 (USD Million)
  • Table. 20 Canada Drug Discovery Outsourcing, by Therapeutics Area, 2018 - 2030 (USD Million)
  • Table. 21 Canada Drug Discovery Outsourcing, by Drug Type, 2018 - 2030 (USD Million)
  • Table. 22 Canada Drug Discovery Outsourcing, by Service Type, 2018 - 2030 (USD Million)
  • Table. 23 Canada Drug Discovery Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table. 24 Mexico Drug Discovery Outsourcing, by Workflow, 2018 - 2030 (USD Million)
  • Table. 25 Mexico Drug Discovery Outsourcing, by Therapeutics Area, 2018 - 2030 (USD Million)
  • Table. 26 Mexico Drug Discovery Outsourcing, by Drug Type, 2018 - 2030 (USD Million)
  • Table. 27 Mexico Drug Discovery Outsourcing, by Service Type, 2018 - 2030 (USD Million)
  • Table. 28 Mexico Drug Discovery Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table. 29 Europe Discovery Outsourcing, by Country, 2018 - 2030 (USD Million)
  • Table. 30 Europe Drug Discovery Outsourcing, by Workflow, 2018 - 2030 (USD Million)
  • Table. 31 Europe Drug Discovery Outsourcing, by Therapeutics Area, 2018 - 2030 (USD Million)
  • Table. 32 Europe Drug Discovery Outsourcing, by Drug Type, 2018 - 2030 (USD Million)
  • Table. 33 Europe Drug Discovery Outsourcing, by Service Type, 2018 - 2030 (USD Million)
  • Table. 34 Europe Drug Discovery Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table. 35 Germany Drug Discovery Outsourcing, by Workflow, 2018 - 2030 (USD Million)
  • Table. 36 Germany Drug Discovery Outsourcing, by Therapeutics Area, 2018 - 2030 (USD Million)
  • Table. 37 Germany Drug Discovery Outsourcing, by Drug Type, 2018 - 2030 (USD Million)
  • Table. 38 Germany Drug Discovery Outsourcing, by Service Type, 2018 - 2030 (USD Million)
  • Table. 39 Germany Drug Discovery Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table. 40 UK Drug Discovery Outsourcing, by Workflow, 2018 - 2030 (USD Million)
  • Table. 41 UK Drug Discovery Outsourcing, by Therapeutics Area, 2018 - 2030 (USD Million)
  • Table. 42 UK Drug Discovery Outsourcing, by Drug Type, 2018 - 2030 (USD Million)
  • Table. 43 UK Drug Discovery Outsourcing, by Service Type, 2018 - 2030 (USD Million)
  • Table. 44 UK Drug Discovery Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table. 45 France Drug Discovery Outsourcing, by Workflow, 2018 - 2030 (USD Million)
  • Table. 46 France Drug Discovery Outsourcing, by Therapeutics Area, 2018 - 2030 (USD Million)
  • Table. 47 France Drug Discovery Outsourcing, by Drug Type, 2018 - 2030 (USD Million)
  • Table. 48 France Drug Discovery Outsourcing, by Service Type, 2018 - 2030 (USD Million)
  • Table. 49 France Drug Discovery Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table. 50 Italy Drug Discovery Outsourcing, by Workflow, 2018 - 2030 (USD Million)
  • Table. 51 Italy Drug Discovery Outsourcing, by Therapeutics Area, 2018 - 2030 (USD Million)
  • Table. 52 Italy Drug Discovery Outsourcing, by Drug Type, 2018 - 2030 (USD Million)
  • Table. 53 Italy Drug Discovery Outsourcing, by Service Type, 2018 - 2030 (USD Million)
  • Table. 54 Italy Drug Discovery Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table. 55 Spain Drug Discovery Outsourcing, by Workflow, 2018 - 2030 (USD Million)
  • Table. 56 Spain Drug Discovery Outsourcing, by Therapeutics Area, 2018 - 2030 (USD Million)
  • Table. 57 Spain Drug Discovery Outsourcing, by Drug Type, 2018 - 2030 (USD Million)
  • Table. 58 Spain Drug Discovery Outsourcing, by Service Type, 2018 - 2030 (USD Million)
  • Table. 59 Spain Drug Discovery Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table. 60 Netherland Drug Discovery Outsourcing, by Workflow, 2018 - 2030 (USD Million)
  • Table. 61 Netherland Drug Discovery Outsourcing, by Therapeutics Area, 2018 - 2030 (USD Million)
  • Table. 62 Netherland Drug Discovery Outsourcing, by Drug Type, 2018 - 2030 (USD Million)
  • Table. 63 Netherland Drug Discovery Outsourcing, by Service Type, 2018 - 2030 (USD Million)
  • Table. 64 Netherland Drug Discovery Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table. 65 Belgium Drug Discovery Outsourcing, by Workflow, 2018 - 2030 (USD Million)
  • Table. 66 Belgium Drug Discovery Outsourcing, by Therapeutics Area, 2018 - 2030 (USD Million)
  • Table. 67 Belgium Drug Discovery Outsourcing, by Drug Type, 2018 - 2030 (USD Million)
  • Table. 68 Belgium Drug Discovery Outsourcing, by Service Type, 2018 - 2030 (USD Million)
  • Table. 69 Belgium Drug Discovery Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table. 70 Switzerland Drug Discovery Outsourcing, by Workflow, 2018 - 2030 (USD Million)
  • Table. 71 Switzerland Drug Discovery Outsourcing, by Therapeutics Area, 2018 - 2030 (USD Million)
  • Table. 72 Switzerland Drug Discovery Outsourcing, by Drug Type, 2018 - 2030 (USD Million)
  • Table. 73 Switzerland Drug Discovery Outsourcing, by Service Type, 2018 - 2030 (USD Million)
  • Table. 74 Switzerland Drug Discovery Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table. 75 Russia Drug Discovery Outsourcing, by Workflow, 2018 - 2030 (USD Million)
  • Table. 76 Russia Drug Discovery Outsourcing, by Therapeutics Area, 2018 - 2030 (USD Million)
  • Table. 77 Russia Drug Discovery Outsourcing, by Drug Type, 2018 - 2030 (USD Million)
  • Table. 78 Russia Drug Discovery Outsourcing, by Service Type, 2018 - 2030 (USD Million)
  • Table. 79 Russia Drug Discovery Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table. 80 Sweden Drug Discovery Outsourcing, by Workflow, 2018 - 2030 (USD Million)
  • Table. 81 Sweden Drug Discovery Outsourcing, by Therapeutics Area, 2018 - 2030 (USD Million)
  • Table. 82 Sweden Drug Discovery Outsourcing, by Drug Type, 2018 - 2030 (USD Million)
  • Table. 83 Sweden Drug Discovery Outsourcing, by Service Type, 2018 - 2030 (USD Million)
  • Table. 84 Sweden Drug Discovery Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table. 85 Asia Pacific Discovery Outsourcing, by Country, 2018 - 2030 (USD Million)
  • Table. 86 Asia Pacific Drug Discovery Outsourcing, by Workflow, 2018 - 2030 (USD Million)
  • Table. 87 Asia Pacific Drug Discovery Outsourcing, by Therapeutics Area, 2018 - 2030 (USD Million)
  • Table. 88 Asia Pacific Drug Discovery Outsourcing, by Drug Type, 2018 - 2030 (USD Million)
  • Table. 89 Asia Pacific Drug Discovery Outsourcing, by Service Type, 2018 - 2030 (USD Million)
  • Table. 90 Asia Pacific Drug Discovery Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table. 91 Japan Drug Discovery Outsourcing, by Workflow, 2018 - 2030 (USD Million)
  • Table. 92 Japan Drug Discovery Outsourcing, by Therapeutics Area, 2018 - 2030 (USD Million)
  • Table. 93 Japan Drug Discovery Outsourcing, by Drug Type, 2018 - 2030 (USD Million)
  • Table. 94 Japan Drug Discovery Outsourcing, by Service Type, 2018 - 2030 (USD Million)
  • Table. 95 Japan Drug Discovery Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table. 96 China Drug Discovery Outsourcing, by Workflow, 2018 - 2030 (USD Million)
  • Table. 97 China Drug Discovery Outsourcing, by Therapeutics Area, 2018 - 2030 (USD Million)
  • Table. 98 China Drug Discovery Outsourcing, by Drug Type, 2018 - 2030 (USD Million)
  • Table. 99 China Drug Discovery Outsourcing, by Service Type, 2018 - 2030 (USD Million)
  • Table. 100 China Drug Discovery Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table. 101 India Drug Discovery Outsourcing, by Workflow, 2018 - 2030 (USD Million)
  • Table. 102 India Drug Discovery Outsourcing, by Therapeutics Area, 2018 - 2030 (USD Million)
  • Table. 103 India Drug Discovery Outsourcing, by Drug Type, 2018 - 2030 (USD Million)
  • Table. 104 India Drug Discovery Outsourcing, by Service Type, 2018 - 2030 (USD Million)
  • Table. 105 India Drug Discovery Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table. 106 Thailand Drug Discovery Outsourcing, by Workflow, 2018 - 2030 (USD Million)
  • Table. 107 Thailand Drug Discovery Outsourcing, by Therapeutics Area, 2018 - 2030 (USD Million)
  • Table. 108 Thailand Drug Discovery Outsourcing, by Drug Type, 2018 - 2030 (USD Million)
  • Table. 109 Thailand Drug Discovery Outsourcing, by Service Type, 2018 - 2030 (USD Million)
  • Table. 110 Thailand Drug Discovery Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table. 111 South Korea Drug Discovery Outsourcing, by Workflow, 2018 - 2030 (USD Million)
  • Table. 112 South Korea Drug Discovery Outsourcing, by Therapeutics Area, 2018 - 2030 (USD Million)
  • Table. 113 South Korea Drug Discovery Outsourcing, by Drug Type, 2018 - 2030 (USD Million)
  • Table. 114 South Korea Drug Discovery Outsourcing, by Service Type, 2018 - 2030 (USD Million)
  • Table. 115 South Korea Drug Discovery Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table. 116 Australia Drug Discovery Outsourcing, by Workflow, 2018 - 2030 (USD Million)
  • Table. 117 Australia Drug Discovery Outsourcing, by Therapeutics Area, 2018 - 2030 (USD Million)
  • Table. 118 Australia Drug Discovery Outsourcing, by Drug Type, 2018 - 2030 (USD Million)
  • Table. 119 Australia Drug Discovery Outsourcing, by Service Type, 2018 - 2030 (USD Million)
  • Table. 120 Australia Drug Discovery Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table. 121 Malaysia Drug Discovery Outsourcing, by Workflow, 2018 - 2030 (USD Million)
  • Table. 122 Malaysia Drug Discovery Outsourcing, by Therapeutics Area, 2018 - 2030 (USD Million)
  • Table. 123 Malaysia Drug Discovery Outsourcing, by Drug Type, 2018 - 2030 (USD Million)
  • Table. 124 Malaysia Drug Discovery Outsourcing, by Service Type, 2018 - 2030 (USD Million)
  • Table. 125 Malaysia Drug Discovery Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table. 126 Indonesia Drug Discovery Outsourcing, by Workflow, 2018 - 2030 (USD Million)
  • Table. 127 Indonesia Drug Discovery Outsourcing, by Therapeutics Area, 2018 - 2030 (USD Million)
  • Table. 128 Indonesia Drug Discovery Outsourcing, by Drug Type, 2018 - 2030 (USD Million)
  • Table. 129 Indonesia Drug Discovery Outsourcing, by Service Type, 2018 - 2030 (USD Million)
  • Table. 130 Indonesia Drug Discovery Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table. 131 Singapore Drug Discovery Outsourcing, by Workflow, 2018 - 2030 (USD Million)
  • Table. 132 Singapore Drug Discovery Outsourcing, by Therapeutics Area, 2018 - 2030 (USD Million)
  • Table. 133 Singapore Drug Discovery Outsourcing, by Drug Type, 2018 - 2030 (USD Million)
  • Table. 134 Singapore Drug Discovery Outsourcing, by Service Type, 2018 - 2030 (USD Million)
  • Table. 135 Singapore Drug Discovery Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table. 136 Philippines Drug Discovery Outsourcing, by Workflow, 2018 - 2030 (USD Million)
  • Table. 137 Philippines Drug Discovery Outsourcing, by Therapeutics Area, 2018 - 2030 (USD Million)
  • Table. 138 Philippines Drug Discovery Outsourcing, by Drug Type, 2018 - 2030 (USD Million)
  • Table. 139 Philippines Drug Discovery Outsourcing, by Service Type, 2018 - 2030 (USD Million)
  • Table. 140 Philippines Drug Discovery Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table. 141 Latin America Discovery Outsourcing, by Country, 2018 - 2030 (USD Million)
  • Table. 142 Latin America Drug Discovery Outsourcing, by Workflow, 2018 - 2030 (USD Million)
  • Table. 143 Latin America Drug Discovery Outsourcing, by Therapeutics Area, 2018 - 2030 (USD Million)
  • Table. 144 Latin America Drug Discovery Outsourcing, by Drug Type, 2018 - 2030 (USD Million)
  • Table. 145 Latin America Drug Discovery Outsourcing, by Service Type, 2018 - 2030 (USD Million)
  • Table. 146 Latin America Drug Discovery Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table. 147 Brazil Drug Discovery Outsourcing, by Workflow, 2018 - 2030 (USD Million)
  • Table. 148 Brazil Drug Discovery Outsourcing, by Therapeutics Area, 2018 - 2030 (USD Million)
  • Table. 149 Brazil Drug Discovery Outsourcing, by Drug Type, 2018 - 2030 (USD Million)
  • Table. 150 Brazil Drug Discovery Outsourcing, by Service Type, 2018 - 2030 (USD Million)
  • Table. 151 Brazil Drug Discovery Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table. 152 Argentina Drug Discovery Outsourcing, by Workflow, 2018 - 2030 (USD Million)
  • Table. 153 Argentina Drug Discovery Outsourcing, by Therapeutics Area, 2018 - 2030 (USD Million)
  • Table. 154 Argentina Drug Discovery Outsourcing, by Drug Type, 2018 - 2030 (USD Million)
  • Table. 155 Argentina Drug Discovery Outsourcing, by Service Type, 2018 - 2030 (USD Million)
  • Table. 156 Argentina Drug Discovery Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table. 157 Colombia Drug Discovery Outsourcing, by Workflow, 2018 - 2030 (USD Million)
  • Table. 158 Colombia Drug Discovery Outsourcing, by Therapeutics Area, 2018 - 2030 (USD Million)
  • Table. 159 Colombia Drug Discovery Outsourcing, by Drug Type, 2018 - 2030 (USD Million)
  • Table. 160 Colombia Drug Discovery Outsourcing, by Service Type, 2018 - 2030 (USD Million)
  • Table. 161 Colombia Drug Discovery Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table. 162 Chile Drug Discovery Outsourcing, by Workflow, 2018 - 2030 (USD Million)
  • Table. 163 Chile Drug Discovery Outsourcing, by Therapeutics Area, 2018 - 2030 (USD Million)
  • Table. 164 Chile Drug Discovery Outsourcing, by Drug Type, 2018 - 2030 (USD Million)
  • Table. 165 Chile Drug Discovery Outsourcing, by Service Type, 2018 - 2030 (USD Million)
  • Table. 166 Chile Drug Discovery Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table. 167 Middle East & Africa Discovery Outsourcing, by Country, 2018 - 2030 (USD Million)
  • Table. 168 Middle East & Africa Drug Discovery Outsourcing, by Workflow, 2018 - 2030 (USD Million)
  • Table. 169 Middle East & Africa Drug Discovery Outsourcing, by Therapeutics Area, 2018 - 2030 (USD Million)
  • Table. 170 Middle East & Africa Drug Discovery Outsourcing, by Drug Type, 2018 - 2030 (USD Million)
  • Table. 171 Middle East & Africa Drug Discovery Outsourcing, by Service Type, 2018 - 2030 (USD Million)
  • Table. 172 Middle East & Africa Drug Discovery Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table. 173 South Africa Drug Discovery Outsourcing, by Workflow, 2018 - 2030 (USD Million)
  • Table. 174 South Africa Drug Discovery Outsourcing, by Therapeutics Area, 2018 - 2030 (USD Million)
  • Table. 175 South Africa Drug Discovery Outsourcing, by Drug Type, 2018 - 2030 (USD Million)
  • Table. 176 South Africa Drug Discovery Outsourcing, by Service Type, 2018 - 2030 (USD Million)
  • Table. 177 South Africa Drug Discovery Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table. 178 Saudi Arabia Drug Discovery Outsourcing, by Workflow, 2018 - 2030 (USD Million)
  • Table. 179 Saudi Arabia Drug Discovery Outsourcing, by Therapeutics Area, 2018 - 2030 (USD Million)
  • Table. 180 Saudi Arabia Drug Discovery Outsourcing, by Drug Type, 2018 - 2030 (USD Million)
  • Table. 181 Saudi Arabia Drug Discovery Outsourcing, by Service Type, 2018 - 2030 (USD Million)
  • Table. 182 Saudi Arabia Drug Discovery Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table. 183 UAE Drug Discovery Outsourcing, by Workflow, 2018 - 2030 (USD Million)
  • Table. 184 UAE Drug Discovery Outsourcing, by Therapeutics Area, 2018 - 2030 (USD Million)
  • Table. 185 UAE Drug Discovery Outsourcing, by Drug Type, 2018 - 2030 (USD Million)
  • Table. 186 UAE Drug Discovery Outsourcing, by Service Type, 2018 - 2030 (USD Million)
  • Table. 187 UAE Drug Discovery Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table. 188 Israel Drug Discovery Outsourcing, by Workflow, 2018 - 2030 (USD Million)
  • Table. 189 Israel Drug Discovery Outsourcing, by Therapeutics Area, 2018 - 2030 (USD Million)
  • Table. 190 Israel Drug Discovery Outsourcing, by Drug Type, 2018 - 2030 (USD Million)
  • Table. 191 Israel Drug Discovery Outsourcing, by Service Type, 2018 - 2030 (USD Million)
  • Table. 192 Israel Drug Discovery Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table. 193 Egypt Drug Discovery Outsourcing, by Workflow, 2018 - 2030 (USD Million)
  • Table. 194 Egypt Drug Discovery Outsourcing, by Therapeutics Area, 2018 - 2030 (USD Million)
  • Table. 195 Egypt Drug Discovery Outsourcing, by Drug Type, 2018 - 2030 (USD Million)
  • Table. 196 Egypt Drug Discovery Outsourcing, by Service Type, 2018 - 2030 (USD Million)
  • Table. 197 Egypt Drug Discovery Outsourcing, by End Use, 2018 - 2030 (USD Million)
  • Table. 198 Regulations for pharmaceutical Workflows and Drug Types in the U.S.
  • Table. 199 Financial performance

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Market formulation & validation
  • Fig. 6 Commodity flow analysis
  • Fig. 7 Value-chain-based sizing & forecasting
  • Fig. 8 QFD model sizing & forecasting
  • Fig. 9 Bottom-up approach
  • Fig. 10 Market snapshot
  • Fig. 11 Segment snapshot 1
  • Fig. 12 Segment snapshot 2
  • Fig. 13 Competitive landscape snapshot
  • Fig. 14 Parent market outlook, 2024 (USD Billion)
  • Fig. 15 Ancillary market outlook, 2024 (USD Billion)
  • Fig. 16 Drug discovery outsourcing market dynamics
  • Fig. 17 Porter's five forces analysis
  • Fig. 18 PESTEL analysis
  • Fig. 19 Drug Discovery Outsourcing market: Workflow outlook and key takeaways
  • Fig. 20 Clinical Trial Biorepository & Archiving Solutions market: Workflow movement analysis
  • Fig. 21 Target Identification & Screening market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Target Validation & Functional Informatics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Lead Identification & Candidate Optimization market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Preclinical Development market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Other Associated Workflow market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Drug Discovery Outsourcing market: Therapeutics Area outlook and key takeaways
  • Fig. 27 Clinical Trial Biorepository & Archiving Solutions market: Therapeutics Area movement analysis
  • Fig. 28 Respiratory system market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Pain and Anesthesia market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Oncology market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 Ophthalmology market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Hematology market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 Cardiovascular market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 34 Endocrine market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 35 Gastrointestinal market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 Immunomodulation market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Anti-infective market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 38 Central Nervous System market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 39 Dermatology market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 40 Genitourinary System market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 41 Drug Discovery Outsourcing market: Drug Type outlook and key takeaways
  • Fig. 42 Clinical Trial Biorepository & Archiving Solutions market: Drug Type movement analysis
  • Fig. 43 Small Molecules market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 44 Large Molecules (Biopharmaceuticals) market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 45 Drug Discovery Outsourcing market: Service Type outlook and key takeaways
  • Fig. 46 Clinical Trial Biorepository & Archiving Solutions market: Service Type movement analysis
  • Fig. 47 Chemistry Services market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 48 Biology Services market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 49 Drug Discovery Outsourcing market: End Use outlook and key takeaways
  • Fig. 50 Clinical Trial Biorepository & Archiving Solutions market: End Use movement analysis
  • Fig. 51 Academic Institutes market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 52 Regional Marketplace: Key Takeaways
  • Fig. 53 North America drug discovery outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Key country dynamics
  • Fig. 55 U.S. drug discovery outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Key country dynamics
  • Fig. 57 Canada drug discovery outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Key country dynamics
  • Fig. 59 Mexico drug discovery outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Europe drug discovery outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Key country dynamics
  • Fig. 62 UK drug discovery outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Key country dynamics
  • Fig. 64 Germany drug discovery outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 Key country dynamics
  • Fig. 66 France drug discovery outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 Key country dynamics
  • Fig. 68 Italy drug discovery outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 69 Key country dynamics
  • Fig. 70 Spain drug discovery outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 71 Key country dynamics
  • Fig. 72 Netherland outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 Key country dynamics
  • Fig. 74 Belgium outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 75 Key country dynamics
  • Fig. 76 Switzerland outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 77 Key country dynamics
  • Fig. 78 Russia outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 Key country dynamics
  • Fig. 80 Sweden outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 81 Key country dynamics
  • Fig. 82 Denmark drug discovery outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 83 Key country dynamics
  • Fig. 84 Asia Pacific drug discovery outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 85 Key country dynamics
  • Fig. 86 Japan drug discovery outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 87 Key country dynamics
  • Fig. 88 China drug discovery outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 89 Key country dynamics
  • Fig. 90 India drug discovery outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 91 Key country dynamics
  • Fig. 92 Thailand drug discovery outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 93 Key country dynamics
  • Fig. 94 South Korea drug discovery outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 95 Key country dynamics
  • Fig. 96 Australia drug discovery outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 97 Key country dynamics
  • Fig. 98 Malaysia drug discovery outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 99 Key country dynamics
  • Fig. 100 Indonesia drug discovery outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 101 Key country dynamics
  • Fig. 102 Singapore drug discovery outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 103 Key country dynamics
  • Fig. 104 Philippines drug discovery outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 105 Latin America drug discovery outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 106 Key country dynamics
  • Fig. 107 Brazil drug discovery outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 108 Key country dynamics
  • Fig. 109 Argentina drug discovery outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 110 Key country dynamics
  • Fig. 111 Colombia drug discovery outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 112 Key country dynamics
  • Fig. 113 Chile drug discovery outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 114 MEA drug discovery outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 115 Key country dynamics
  • Fig. 116 South Africa drug discovery outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 117 Fig. Key country dynamics
  • Fig. 118 Saudi Arabia drug discovery outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 119 Key country dynamics
  • Fig. 120 UAE drug discovery outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 121 Key country dynamics
  • Fig. 122 Israel drug discovery outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 123 Key country dynamics
  • Fig. 124 Egypt drug discovery outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 125 Key country dynamics
  • Fig. 126 Kuwait drug discovery outsourcing market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 127 Key company categorization
  • Fig. 128 Service heat map analysis
  • Fig. 129 Strategic framework